{"id":536255,"date":"2021-09-09T08:04:32","date_gmt":"2021-09-09T12:04:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/"},"modified":"2021-09-09T08:04:32","modified_gmt":"2021-09-09T12:04:32","slug":"yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/","title":{"rendered":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference"},"content":{"rendered":"
\n

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd<\/sup> Global Investment Conference.<\/p>\n

The presentation will be available on-demand via the conference portal and through the Company’s website at\u00a0www.yumanity.com\/events<\/u><\/a>\u00a0beginning at 7 a.m. EDT, September 13.<\/p>\n

\n About Yumanity Therapeutics<\/strong>
\n
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity\u2019s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\u2019s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\u2019s disease. For more information, please visit\u00a0www.yumanity.com<\/u><\/a>.<\/p>\n

\n Investors:<\/strong>
\n
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006<\/p>\n

\n Media:<\/strong>
\n
Burns McClellan, Inc.
Robert Flamm, Ph.D. \/ Harrison Wong
rflamm@burnsmc.com<\/a> \/ hwong@burnsmc.com<\/a>
(212) 213-0006 ext. 364 \/ 316<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Company’s website at\u00a0www.yumanity.com\/events\u00a0beginning at 7 a.m. EDT, September 13. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug … <\/p>\n

Continue reading “Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nYumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Company’s website at\u00a0www.yumanity.com\/events\u00a0beginning at 7 a.m. EDT, September 13. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug … Continue reading "Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference\",\"datePublished\":\"2021-09-09T12:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/\"},\"wordCount\":229,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/\",\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=\",\"datePublished\":\"2021-09-09T12:04:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk","og_description":"BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Company’s website at\u00a0www.yumanity.com\/events\u00a0beginning at 7 a.m. EDT, September 13. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug … Continue reading \"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:04:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference","datePublished":"2021-09-09T12:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/"},"wordCount":229,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/","name":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=","datePublished":"2021-09-09T12:04:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjc0NiM0Mzk0OTY3IzIyMDAzMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-23rd-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}